<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02340195</url>
  </required_header>
  <id_info>
    <org_study_id>14916A</org_study_id>
    <secondary_id>2012-005647-25</secondary_id>
    <nct_id>NCT02340195</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function</brief_title>
  <official_title>Interventional, Single-site, Open-label, Reduced/Staged, Multiple-dose Study Investigating the Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Patients With Renal Impairment and in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics properties of idalopirdine
      following multiple dosing in patients with renal impairment and compare to those in healthy
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the LuAE58054 plasma concentration-time curve from time zero to 24h(AUC0-24)</measure>
    <time_frame>Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of Lu AE58054</measure>
    <time_frame>0-12 hours day 10</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Idalopirdine (Lu AE58054) 60 mg (Group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 patients with severe renal impairment and not on dialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idalopirdine (Lu AE58054) 60 mg (Group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idalopirdine (Lu AE58054) 60 mg (Group C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B
8 patients with moderate renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idalopirdine (Lu AE58054) 60 mg (Group D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group D will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B
8 patients with mild renal impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idalopirdine (Lu AE58054) 60 mg</intervention_name>
    <description>encapsulated film-coated tablets for oral use once daily for 10 days</description>
    <arm_group_label>Idalopirdine (Lu AE58054) 60 mg (Group A)</arm_group_label>
    <arm_group_label>Idalopirdine (Lu AE58054) 60 mg (Group B)</arm_group_label>
    <arm_group_label>Idalopirdine (Lu AE58054) 60 mg (Group C)</arm_group_label>
    <arm_group_label>Idalopirdine (Lu AE58054) 60 mg (Group D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged between 50 and 75 years (inclusive)

          -  BMI ≥18.5 kg/m2 and ≤32 kg/m2 at the Screening Visit.

          -  Group A: Patients with severe renal impairment renal impairment (creatinine clearance
             (ClCr) ≤29 mL/min)

          -  Group B: Healthy subjects with normal kidney function (creatinine clearance (ClCr) ≥90
             mL/min, inclusive)

          -  Group C: Patients with moderate renal impairment ((creatinine clearance between 30 -
             59 mL/min, inclusive)

          -  Group D: Patients with mild renal impairment (Creatinine clearance between 60 - 89
             mL/min, inclusive)

        Exclusion Criteria:

        •The subject has taken disallowed medication &lt;1 week prior to the first dose of IMP or &lt;5
        half-lives prior to the first dose of IMP for any disallowed medication taken, whichever is
        longer)

        Other protocol defined inclusion and exclusion criteria do apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DE801</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2015</study_first_posted>
  <last_update_submitted>November 6, 2015</last_update_submitted>
  <last_update_submitted_qc>November 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

